Published 1 hour ago • loading... • Updated 7 hours ago
JAMA Study Finds Abortion Bans Reduce Miscarriage Treatment Options
The first national study found a 2.2-point drop in miscarriage medication use and a 13.8-point rise in misoprostol-only treatment in ban states.
A new study published Monday in JAMA reveals that abortion bans reduce access to quality miscarriage care, tracking 123,598 patient cases between 2018 and 2024.
In 14 states with trigger bans, patients experienced a 2.8 percentage point increase in expectant management and a 2.2 percentage point decrease in medication management compared to 17 comparison states.
Patients in ban states were 13.8 percentage points more likely to receive less-effective misoprostol-only regimens rather than the evidence-based mifepristone-misoprostol combination, according to Maria Rodriguez, MD, MPH, of Oregon Health & Science University in Portland.
Rodriguez stated, "We cannot silo abortion care from pregnancy care," noting direct clinical implications, while Daniel Grossman, MD, of the Advancing New Standards in Reproductive Health at the University of California San Francisco, called the findings "concerning."
Anti-Abortion activists continue pressing the Trump administration for further mifepristone restrictions as states like Oklahoma and Louisiana enact stricter laws. On Thursday, the Supreme Court blocked one lower court order, though other legal challenges persist.